Lymphomas | Oncology Today with Dr Neil Love: Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting

Featuring perspectives from Dr Matthew Lunning, including the following topics:

• Potential role of polatuzumab vedotin/R-CHP in therapy for previously untreated diffuse large B-cell lymphoma (DLBCL) (00:00)

• Association between metabolic tumor volume and clinical outcomes with loncastuximab tesirine in the LOTIS-2 trial and axicabtagene ciloleucel in the ZUMA-7 trial (10:54)

• Chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas: Activity, tolerability and patient selection (22:16)

• Efficacy of and durable complete responses with bispecific antibodies in patients with DLBCL (36:48)

• Five-year results and overall survival update from the Phase III AUGMENT study evaluating rituximab and lenalidomide (R2) versus rituximab and placebo for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (42:44)

• Activity and safety of tazemetostat in combination with (R2) in patients with R/R follicular lymphoma (FL) (44:52)

• Long-term clinical outcomes with CAR T-cell therapies for patients with R/R FL (46:50)

• Available data with and ongoing studies of bispecific antibodies for R/R FL (50:23)

• Design and outcomes of the SHINE and TRIANGLE studies in mantle cell lymphoma (MCL); evolving role of transplantation for MCL (1:00:38)

• Real-time monitoring of minimal residual disease in patients receiving acalabrutinib with (R2) for treatment-naïve MCL (1:13:29)

• Assessment of durable responses after brexucabtagene autoleucel for R/R MCL in the ZUMA-2 trial (1:15:29)

• High complete response rates with glofitamab for patients with heavily pretreated MCL (1:19:00)

• Nivolumab with ICE (ifosfamide/carboplatin/etoposide) as first salvage therapy for patients with high-risk R/R Hodgkin lymphoma (1:21:04)

• Efficacy and safety of camidanlumab tesirine in patients with R/R classical Hodgkin lymphoma (1:23:07)

• Importance of brain-to-vein time in patients receiving CAR T-cell therapy (1:25:37)

CME information and select publications